Fig. 2.

Mean percent change from baseline in serum, intracellular, and urinary magnesium with bardoxolone methyl in the pharmacodynamic study. Results from an open-label pharmacodynamic study in patients (n = 24) with T2DM and stage 3b-4 CKD. Data plotted are mean ± SE percent changes from baseline in serum (black), red blood cell (red), sublingual epithelial cell (green), and urine (blue) magnesium levels in patients administered bardoxolone methyl (through study day 56) and post-treatment (study day 84). **p < 0.01 vs. baseline. Values are plotted as mean ± SEM at baseline (n = 24), study day 24 (n = 21), and study day 56 (n = 20).